Collaborative Success with Boehringer Ingelheim

Driving Innovation in Preclinical Research: Collaboration with Boehringer Ingelheim 

At Biorizon Consulting, we’re excited to share the success story of a preclinical trial led by our Founder and Director, Dr. Laura-Marie Zimmermann, in partnership with Boehringer Ingelheim through their open innovation portal, opnMe. This collaboration exemplifies the power of open science and innovation in advancing critical preclinical research, paving the way for meaningful discoveries in disease biology.

In her work, Dr. Zimmermann accessed a potent compound from Boehringer Ingelheim’s opnMe platform, transforming her trial’s trajectory. “The team consistently went the extra mile to provide me with tailored guidance that enhanced my work, transforming our relationship into a true partnership,” says Dr. Zimmermann. This collaboration empowered the preclinical trial by providing a precisely suited compound, which became instrumental in overcoming complex research challenges and achieving significant results.

Through her dedication and expertise, Dr. Zimmermann discovered that collagenase matrix metalloprotease 13 (MMP-13) plays a critical role in aneurysm formation in preclinical models of Marfan syndrome. This insight offers a deeper understanding of aneurysm biology and demonstrates the impact of combining open-access compounds with strategic, data-driven preclinical trials.

Curious to read the full story? Dive into Dr. Zimmermann’s findings and learn more about the unique offerings of Boehringer Ingelheim’s #opnMe portal here (note: content is in German).

To hear Dr. Laura-Marie Zimmermann share her experience with Boehringer Ingelheim’s #opnMe platform, check out the video on LinkedIn here. In the video, she shares how this collaboration became essential to her preclinical trial, enabling pivotal discoveries and impactful research outcomes.